Immuneering (IMRX) Operating Income (2020 - 2023)
Historic Operating Income for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$16.3 million.
- Immuneering's Operating Income fell 1656.76% to -$16.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$58.4 million, marking a year-over-year decrease of 1288.63%. This contributed to the annual value of -$58.4 million for FY2023, which is 1288.63% down from last year.
- As of Q4 2023, Immuneering's Operating Income stood at -$16.3 million, which was down 1656.76% from -$13.9 million recorded in Q3 2023.
- In the past 5 years, Immuneering's Operating Income registered a high of -$3.6 million during Q2 2020, and its lowest value of -$16.3 million during Q4 2023.
- Moreover, its 4-year median value for Operating Income was -$11.6 million (2022), whereas its average is -$10.5 million.
- Its Operating Income has fluctuated over the past 5 years, first crashed by 12156.21% in 2021, then tumbled by 559.74% in 2023.
- Over the past 4 years, Immuneering's Operating Income (Quarter) stood at -$5.8 million in 2020, then crashed by 90.45% to -$11.1 million in 2021, then dropped by 25.81% to -$14.0 million in 2022, then fell by 16.57% to -$16.3 million in 2023.
- Its last three reported values are -$16.3 million in Q4 2023, -$13.9 million for Q3 2023, and -$13.5 million during Q2 2023.